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Background: Partly because of functional genomics, there has been a major paradigm shift from solely thinking of
skeletal muscle as contractile machinery to an understanding that it can have roles in paracrine and endocrine
functions. Physical inactivity is an established risk factor for some blood clotting disorders. The effects of inactivity
during sitting are most alarming when a person develops the enigmatic condition in the legs called deep venous
thrombosis (DVT) or “coach syndrome,” caused in part by muscular inactivity. The goal of this study was to
determine if skeletal muscle expresses genes with roles in hemostasis and if their expression level was responsive to
muscular inactivity such as occurs in prolonged sitting.
Methods: Microarray analyses were performed on skeletal muscle samples from rats and humans to identify genes
associated with hemostatic function that were significantly expressed above background based on multiple probe
sets with perfect and mismatch sequences. Furthermore, we determined if any of these genes were responsive to
models of physical inactivity. Multiple criteria were used to determine differential expression including significant
expression above background, fold change, and non-parametric statistical tests.
Results: These studies demonstrate skeletal muscle tissue expresses at least 17 genes involved in hemostasis. These
include the fibrinolytic factors tetranectin, annexin A2, and tPA; the anti-coagulant factors TFPI, protein C receptor,
PAF acetylhydrolase; coagulation factors, and genes necessary for the posttranslational modification of these
coagulation factors such as vitamin K epoxide reductase. Of special interest, lipid phosphate phosphatase-1 (LPP1/
PAP2A), a key gene for degrading prothrombotic and proinflammatory lysophospholipids, was suppressed locally in
muscle tissue within hours after sitting in humans; this was also observed after acute and chronic physical inactivity
conditions in rats, and exercise was relatively ineffective at counteracting this effect in both species.
Conclusions: These findings suggest that skeletal muscle may play an important role in hemostasis and that
muscular inactivity may contribute to hemostatic disorders not only because of the slowing of blood flow per se,
but also potentially because of the contribution from genes expressed locally in muscles, such as LPP1.
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Low muscular activity has been associated with cardio-
vascular diseases [1,2]. In contrast to the more estab-
lished literature on the effects of formal types of
exercise, there is an emerging interest in the underlying
molecular responses to physical inactivity and the more
common non-exercise activities such as standing and
low-intensity physical activity [3]. Deep venous throm-
bosis (DVT) can occur from an acute lack of normal
ambulatory activity [4-6], and we are unaware of any evi-
dence that it can be prevented by exercise [7,8]. For ex-
ample, it was first reported over 60 years ago that sitting
in London air raid shelters was associated with a 6-fold
increased incidence of DVT [6]. Then, Homans noted in
1954 that the “spontaneous thrombosis which almost ex-
clusively occurs in the legs” is due to “a state imposed
by airplane flights, automobile trips, and even attend-
ance at the theater” [4]. There was a report in that same
decade of a patient with “thrombosis occurring as a re-
sult of prolonged sitting while the patient was watching
television” [5] and the insidious risks of typical amounts
of sitting or other sedentary behavior has continually
been observed [9,10]. Currently, there are ~2 million
cases of DVT reported each year in the United States,
leading to 250,000 deaths due largely to pulmonary em-
bolism [11].
What distinguishes DVT from other forms of throm-
bosis is that it occurs deep in the muscle of the legs. Be-
cause the hypercoagulable state develops locally within
the legs, there has been a long held supposition that dys-
regulation of cellular processes locally in the leg muscle
tissue may somehow contribute to the risk of DVT in
the legs. Support for this proposition would be but-
tressed by the detection of significant hemostatic gene
expression (mRNA) in human skeletal muscle. The first
inkling for this came from a recent report that there is a
pool of tPA protein (tissue plasminogen activator) loca-
lized within the skeletal muscle tissue [12], consistent
with the muscle producing tPA via local gene expres-
sion, but not ruling out the possibility that the protein
was delivered to muscle from the circulation. In
addition, a more recent study reported that skeletal
muscle expressed not only tPA but also 3 additional
hemostasis related genes (CTAP III, tetranectin, and
PAI-1) in overweight men with metabolic syndrome
[13]. Giving a further hint of a role for skeletal muscle
in hemostasis, the expression of these genes was altered
by 9 months of exercise training to result in a pattern
that would be consistent with less risk of thrombosis
[13]. As little is known about the role of skeletal muscle
in hemostasis at this point, determining if skeletal
muscle expresses a number of hemostasis related genes
may open the door toward a new insight for the role of
this tissue in hemostasis. Therefore, the first aim of thisstudy was to comprehensively examine what hemostasis
genes are expressed in skeletal muscle through the use
of microarray technology. Furthermore, we sought to
determine if any of these expressed genes would be
altered by commonly used models of reduced contract-
ile activity in the legs (hindlimb unloading in rats and
sitting in humans). A translational study of rodent and
human skeletal muscle was performed given the even-
tual need for physiological studies inducing thrombosis
in experimental animal models while manipulating ex-
pression of select hemostatic genes. The identification
of a hemostatic gene(s) impacted by prolonged inactivity
like sitting may be important to investigate as a candi-
date for a role in the pathogenesis of DVT.Methodology
Rat experiments
Animal procedures were approved by an Institutional
Animal Care and Use Committee and performed in
respect of the American Physiology Society principles
for research on animals. Female Sprague Dawley rats
(Harlan) weighing approximately 200 g were housed indi-
vidually (450 cm x 241 cm) in a temperature- and light-
controlled environment (12:12 hrs light–dark cycle). The
soleus muscle (deepest skeletal muscle in the rat hind-
limb) was obtained under anesthesia (16.2 mg ketamine,
0.66 mg xylazine, 1.05 mg acepromazine) from all rats and
frozen in liquid nitrogen after the completion of the fol-
lowing described physical activity/inactivity treatments.
Altogether, 89 rats were used in these studies. In the
first set of experiments, the effect of the acute (12 hrs)
removal of normal standing/ambulatory activity on skel-
etal muscle gene expression was tested in rats. Rats with
normal standing and ambulatory cage activity and spon-
taneous movements who never exercised served as con-
trols for these acute experiments (n = 24). Forty-nine
rats were restricted from standing on the hindlimbs for
12 hrs (7 PM to 7 AM, dark cycle) by wrapping 1.5 cm
of the tail with adhesive tape connected to a fishing lure
swivel tied to an overhanging metal rod (hindlimb
unloading). This specific hindlimb unloading model and
effects on muscle have been described previously [14].
The hindlimbs were elevated just enough to prevent the
feet from touching the floor. All rats were acclimatized
to the treatment of hindlimb unloading for at least 2 days
before the experiments (1 hr/day). In order to test if ex-
ercise would quickly reverse the effects of inactivity, 20
of the inactive rats were exercised on a treadmill (8 m/
min) immediately following 12 hours of not standing
(hindlimb unloading). They exercised on a treadmill for
an accumulated duration of two hours (4 x 30 minutes)
over a 4 hour period of time (with allowance for spon-
taneous ambulation and standing in the cage the rest of
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and treadmill exercise.
In the chronic study (11 days), we sought to determine
the impact of reduced muscle use per se as in the acute
study, without the potentially extreme (up to 40%)
muscle atrophy and associated remodeling caused by 1–
2 weeks of continuous muscle disuse in rats [15]. To
successfully accomplish this, 8 rats underwent the hind-
limb unloading procedure for ~10 hrs/day for 11 days,
and then were euthanized 3 hours into the dark cycle.
We previously reported that this completely prevents
the muscle atrophy associated with muscle inactivity
[14]. Eight control rats were euthanized at the same time
of day in order to obtain the soleus muscles.
Human experiments
All subjects volunteered to take part in this study after
being informed of potential risks associated with partici-
pation and providing written consent. This study was
approved by an institutional Internal Review Board.
As in the rats, the effect of ~12 hrs of muscle in-
activity in the legs was studied. The primary study of
inactivity was performed in three healthy adult males
(31 ± 6 years, 69 ± 5 kg, 23.1 ± 0.9 kg/m2; mean ± SD)
who exercised habitually (two subjects bicycled and
one ran 3–4 days/week). Additionally, a more extensive
case study was performed in a healthy 25-year old male as
described in more detail below. On the standing/ambula-
tory control trial, subjects performed normal intermittent
standing/ambulation restricted to light intensity activities.
During the sitting trial, subjects worked on computers,
watched videos, read, used the telephone, talked with
others, and performed other sedentary activities for 12
hours. Subjects stood upright momentarily to use the toi-
let and were not sitting in an awkward position that might
cause abnormal mechanical occlusion, so as to focus on
the underlying singular effects of inactivity on gene ex-
pression. Approximately 100 mg was biopsied from deep
within the vastus lateralis (6–9 cm in depth) after 12
hours of either sitting or after 12 hours of standing/am-
bulatory activity. In order to control for diet and acti-
vity, subject diets were replicated for the two days
preceding each trial and physical activity was well con-
trolled during the two days before each trial by disallowing
any form of exercise. Furthermore, all subjects consumed
identical dinners the night before the experimental trials
and the same breakfast the morning of each experimental
trial and fasted for 12 hours before all biopsy samples.
Lastly, a case study was performed on one subject (66 kg,
21 kg/m2) during 15 days of wheelchair use. He was rec-
reationally active (bicycling) and was estimated to have
a VO2max of 51 ml/kg/min from the heart rate responses
to an incremental cycling ergometer test performed be-
fore he was subject to the physical inactivity treatments.One of his legs remained inactive during this time, while
one leg was exercised daily by a combination of exer-
cises without adding back the natural standing and
other low-intensity physical activity. He performed two
one-legged cycling bouts a day with one being a con-
tinuous 30 minute bout at 68 watts eliciting a rating of
perceived exertion (RPE) of 12 (Borg scale) and another
30 minute session that included four 5-minute intervals
at 108 watts eliciting an RPE of 15 (hard). He also per-
formed unilateral resistance exercises at an intensity in
which 6 sets of 20 repetitions could be completed with
voluntary fatigue. Because of the potential concern for
heterogeneity between biopsies within the same per-
sons, we obtained duplicate biopsies (one in each leg
from approximately the same area) to ascertain variabil-
ity, and the mean inter-biopsy coefficient of variation
for LPP1 gene expression was 6.5% (n = 3 duplicate
biopsies).
RNA processing
Muscle was homogenized on ice in TRIzol Reagent
(GIBCO BRL) for three pulses of 15 seconds each, and
total RNA was isolated. For the acute physical inactivity
rat study, 10 mg muscle samples were pooled from 8–10
animals to minimize the impact of individual variability
[16]. From each rat RNA pool or human biopsy, 18 μg
of total RNA was converted into double-stranded cDNA
using the SuperScript Choice system (GIBCO BRL) with
an oligo-dT24 primer containing the T7 RNA polymer-
ase promoter (Genset). Double-stranded cDNA was
purified by phenol/chloroform extraction and precipi-
tated. In vitro transcription was subsequently performed
using an ENZO BioArray RNA transcript labelling kit
(ENZO). Biotin-labeled cRNA was purified by an RNeasy
kit (Qiagen) and fragmented.
There was a total of 3 pools of RNA from the control
rats, 3 pools of RNA from the 12 hr inactive rats, and 2
pools of RNA from the treadmill exercised rats (8–10
rats per pool). For the chronic rat study, RNA proces-
sing yielded 2 pools of RNA from the control rats and 2
pools of RNA from the 11-day inactive rats (4 rats per
pool).
Microarray processing
Ten μg of fragmented biotinylated cRNA was hybridized
for 16 hours on either the Affymetric human U133(A
and B) or the rat U34A microarrays. Each microarray
was washed and stained in the Affymetrix Fluidics Sta-
tion 400 using the manufacturer’s instructions and
reagents. This involved removal of non-hybridized
material followed by incubation with streptavidin-
phycoerythrin (SAPE) to detect hybridized cRNA. The
signal intensity was amplified by a second staining
with biotin-labeled anti-streptavidin antibody followed
Table 1 Hemostatic gene expression in human skeletal muscle tissue




NM_000132.2 Strong detection 8/8 0.00024 Intrinsic pathway of
blood coagulation
Coagulation factor VII NM_000131.2 Strong detection 8/8 0.0016 Activates the coagulation
cascade by converting
factor IX to factor IXa
factor X to factor Xa
coagulation factor VII
Vitamin K epoxide reductase
complex, subunit 1-like 1





NM_012151.2 Strong detection 8/8 0.0020 unknown
von Willebrand factor (VWF) NM_000552.2 Strong detection 8/8 0.005 Serves as a bridge between
platelet glycoprotein
GPIb/IX and collagen
Vitamin K epoxide reductase complex, subunit 1 NM_024006 Moderate detection 8/8 0.014 Required for the carboxylation
of glutamic acid residues in
some blood-clotting proteins
Gamma-glutamyl carboxylase BE326952 Moderate detection 7/8 0.024 Carboxylation of coagulation
factors VII4/8 0.063
Glycoprotein Ib (platelet), alpha polypeptide NM_000173 Moderate detection 4/8 0.051 Binding of the GP Ib-IX-V
complex to VWF facilitates initial
platelet adhesion to vascular
subendothelium after
vascular injury
Coagulation factor XIII, A1 polypeptide NM_000129.2 Moderate detection 3/8 0.068 Last zymogen to become
activated in the blood
coagulation cascade
Thrombin receptor NM_001992.2 Moderate detection 4/8 0.071 Activated on surface of
activated platelets by
prothrombinase complex
Integrin, beta 3 NM_000212 Moderate detection 3/8 0.076 Promotion of the generation
of thrombin by localizing





isoform Ib, alpha subunit
NM_000430.2 Strong detection 8/8 0.00024 Catalyzes the removal of the











Tissue factor pathway inhibitor J03225.1 Strong detection 6/8 0.004 Inhibits tissue factor
3/8 0.076




Thrombomodulin 40288292 Moderate detection 7/8 0.024 Receptor that binds thrombin
activating protein C and
degrades clotting factors
Va and VIIIa
Protein S (alpha) NM_000313 Moderate detection 7/8 0.024 A cofactor to anticoagulant
activated protein C
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Table 1 Hemostatic gene expression in human skeletal muscle tissue (Continued)
Ectonucleoside triphosphate
diphosphohydrolase 1
NM_001776 Moderate detection 1/8 0.081 Endothelial ecto-ADPase
inhibiting platelet function via
hydrolysis of released platelet ADP
FIBRINOLYTIC FUNCTIONS








NM_003278 Strong detection 8/8 0.0022 Bind fibrin and coactivate
plasminogen
Plasminogen activator, urokinase NM_002658 Moderate detection 7/8 0.024 Conversion of plasminogen
to plasmin4/8 0.051




X74039.1 Moderate detection 5/8 0.046 Binds uPA and permits
activation of pro-enzyme
by plasmin
Access # is NCBI accession number. Frequency is the number of biopsy samples showing significant expression out of a total number of 8 biopsies according to
Affymetrix criteria. P-value is the median p-value of the Wilcoxon test for all 8 human biopsy samples. The gene was bolded and the p-value was underlined if it
met the FDR criteria for being significantly detected. Multiple probe sets are available for some genes and are presented in the Table.
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fore and after amplification using a Hewlett-Packard
G2500A Gene Array Scanner.PCR analysis
Aliquots (2 μg) of total RNA from each biopsy were re-
verse transcribed with Superscript II RNase H Reverse
Transcriptase (Invitrogen). PCR was then performed in a
thermocycler (Mastercycler, Eppendorf) using Platinum
Taq DNA Polymerase (Invitrogen). The LPP1 sense primer
was GGT CTT GTT GCC GTA TCC AT and the anti-
sense primer was TCC CAG TTG TTG GTG TTT CA
(214 bp). GAPDH human primer sets (Clontech) were used
to normalize data. Samples were loaded into a 3% agarose
gel and dsDNA was visualized with Sybr Green I nucleic
acid gel stain (Molecular Probes). Bands were quantified
with densitometry using the STORM 860 (Amersham)
scanner and ImageQuant software (Amersham).Statistical analyses
Microarray
Microarray images were analyzed using statistically based
Affymetrix Microarray Suite 5.0 software [17]. In brief, each
interrogated transcript was represented by 11 probe pairs
for the human arrays and 16–20 probe pairs for the rat
arrays. Each probe pair consists of a perfect match se-
quence (PM) that is complementary to the cRNA target
and a mismatch sequence (MM) that includes a change of
a single base critical for hybridization. Bacterial sequences
were also included on the arrays as external controls for
hybridization. Complete transcription and hybridizationwere validated using Affymetrix's recommended criteria
based on the bacterial controls and several housekeeping
genes. Published statistical algorithms [17] were used to de-
termine whether or not a transcript was detectable in a
given sample. Comparison of the hybridization signals from
the PM and MM probes was performed with a one-sided
Wilcoxon sign rank test by the Affymetrix software in order
to determine if a gene was significantly expressed at a p-
value below the false discovery rate (FDR) threshold [18].
The Wilcoxon non-parametric test was chosen because it
is robust, insensitive to outliers, and does not need a nor-
mal data distribution [17]. Using the Affymetrix Net Affyx
publicly available website (using terms such as clotting, co-
agulation, fibrinolysis, and hemostasis) and PubMed, we
searched for the expression of genes related to hemostasis
(Tables 1 and 2) and also ultimately lysophospholipid me-
tabolism (Table 3) after identifying that the expression of
lipid phosphate phosphatase 1 (LPP1) was affected by in-
activity (see below).Differential expression
Several conservative and reliable criteria to define differ-
ential expression were utilized as previously described
for rat tissues [16]. Multiple filters were used including a
present call (p ≤ 0.04), a p-value ≤ false discovery rate
(FDR) criteria and a magnitude of change ≥ 1.5-fold in
the determination of differential expression. The use of
such criteria has been shown to reduce both technical
and biological variation. Normalization between micro-
arrays is performed by the Affymetrix Microarray Suite
5.0 and normalizes the average intensity of both the
Table 2 Hemostatic gene expression in rat skeletal muscle tissue
GENE Access # Expression Frequency P-value Function
COAGULANT FUNCTIONS
Tissue factor U07619 Strong detection 8/8 0.0013 Initiates blood coagulation
cascades, and it functions as
the high-affinity receptor for
the coagulation factor VII
Fibulin 5 NM_019153 Strong detection 8/8 0.0014 Forms complex with fibrinogen
Thrombin receptor M81642 Strong detection 8/8 0.0066 Activated on surface of activated
platelets by prothrombinase
complex
Gamma-glutamyl carboxylase AF065387 Strong detection 7/8 0.021 Carboxylation of coagulation
factors VII
P2Y purinoceptor U22830 Moderate detection 5/8 0.031 Binds ADP and leads to platelet
shape change
Coagulation factor IX M26247 Moderate detection 2/8 0.058 Vit K dependent factor that
activates factor X
Fibrinogen-gamma J00735 Moderate detection 1/8 0.090 Fibrinogen is cleaved by
thrombin to form fibrin
ANTI-COAGULANT FUNCTIONS






NM_022587 Moderate detection 4/8 0.040 Endothelial ecto-ADPase inhibiting
platelet function via hydrolysis of
released platelet ADP
Protein S (alpha) U06230 Moderate detection 2/8 0.044 A cofactor to anticoagulant
activated protein C
Thrombomodulin AF022742 Moderate detection 6/8 0.052 Receptor that binds thrombin
activating protein C and degrades
clotting factors Va and VIIIa
FIBRINOLYTIC FUNCTIONS
Plasminogen activator, tissue M23697 Strong detection 8/8 0.00027 Conversion of plasminogen to
plasmin
Annexin A2 L13039 Strong detection 8/8 0.00064 Profibrinolytic co-receptor for
tissue plasminogen activator and
plasminogen on endothelial cells
Plasminogen activator, urokinase X63434 Strong detection 8/8 0.0026 Conversion of plasminogen to plasmin
Access # is NCBI accession number. Frequency is the number of pools of muscle (n = 10 rats per pool) showing significant expression out of a total number of 8
pools of mRNA. P-value is the median p-value of a Wilcoxon test for all 8 muscle pools. The gene was bolded and the p-value was underlined if it met the FDR
criteria for being significantly detected.
Zderic and Hamilton Lipids in Health and Disease 2012, 11:137 Page 6 of 13
http://www.lipidworld.com/content/11/1/137treatment and control arrays. Unlike the desirable
repeated measures experimental design in the human
study, a cross-sectional study design was performed in
rats (because of the inability to obtain serial biopsies
from each rat). Thus, pooling of RNA for the microar-
rays from a large number of animals was used to
minimize experimental error. For example, approxi-
mately 11 times more genes had a CV > 30% in single
samples than in pooled samples (n = 8-10 per pool) [16].
For the acute rat study, each of the 3 hindlimb unloaded
and the 2 treadmill exercised RNA pools was compared
against each of the 3 control pools which resulted in 9
(3 x 3) comparisons for unloading and 6 (3 x 2) compari-
sons for treadmill exercise. For the chronic study, thetwo hindlimb unloaded pools were compared against the
two control pools which resulted in 4 (2 x 2) compari-
sons. The average p-value from the Wilcoxon sign rank
test of all these comparisons (either 9, 6, or 4 compari-
sons) was then ranked and compared against the FDR
thresholds to determine differential expression [18]. In
addition, only hemostatic related genes that were greater
than 1.5-fold magnitude different between treatment and
control for all the possible comparisons were considered
as differentially expressed. For the human microarray
analyses, only hemostatic related genes that were signifi-
cantly expressed, greater than 1.5-fold different in each
of the participants, and had a p-value from a paired t-test
below 0.05 were considered as differentially expressed.
Table 3 LPP1 related gene expression in human skeletal muscle
GENE Access # Expression Frequency P-value Function
GENE SUPPRESSED BY PHYSICAL INACTIVITY
LPP1 AB000888.1 Strong detection 8/8 0.004 Dephosphorylates LPA, S1P, PA, ceramide-1-P
GENES NOT AFFECTED BY PHYSICAL INACTIVITY
LPP2 AF047760.1 Not detected 0/8 0.47 Dephosphorylates LPA, S1P, PA, ceramide-1-P
LPP3 NM_003713 Strong detection 8/8 0.0007 Dephosphorylates LPA, S1P, PA, ceramide-1-P
8/8 0.0002
LPAP AB031478.1 Moderate detection 2/8 0.068 Dephosphorylates LPA
SGPP1 NM_030791 Moderate detection 7/8 0.024 Dephosphorylates S1P
SGPL1 NM_003901.1 Not detected 0/8 0.90 Irreversible sphingosine 1-phosphate degradation
SPHK1 NM_021972.1 Not detected 0/8 0.19 Phosphorylates sphingosine
AGPAT1 U56417 Strong detection 8/8 0.0029 ER enzyme converting LPA to PA
8/8 0.0056
AGPAT2 U56418 Moderate detection 8/8 0.028 ER enzyme converting LPA to PA
AGPAT3 NM_020132 Strong detection 8/8 0.002 ER enzyme converting LPA to PA
AGPAT4 NM_020133.1 Not detected 0/8 0.25 Converts LPA to PA
LYPLA1 AF077198.1 Strong detection 8/8 0.0002 Hydrolyzes lysophosphatidylcholine to LPA
LYPLA2 NM_007260.1 Strong detection 8/8 0.014 Hydrolyzes lysophosphatidylcholine to LPA
EDG2 45580697 Moderate detection 4/8 0.068 LPA receptor
EDG3 NM_005226 Not detected 0/8 0.43 LPA receptor
EDG4 NM_004720.3 Not detected 0/8 0.63 LPA receptor
EDG7 NM_012152.1 Not detected 0/8 0.33 LPA receptor
EDG8 AF317676 Not detected 0/8 0.97 S-1-P receptor
P2Y9 NM_005296.1 Not detected 0/8 0.63 LPA receptor, platelet
ROCK2 D87931 Strong detection 7/8 0.010 LPA activated kinase
Access # is NCBI accession number. Frequency is the number of biopsy samples showing significant expression out of a total number of 8 biopsies. P-value is the
median p-value of a Wilcoxon test for all 8 human biopsy samples. The gene was bolded and the p-value was underlined if it met the FDR criteria for being
significantly detected. Multiple probe sets are available for some genes and are presented in the Table. ER, endoplasmic reticulum; LPA, lysophosphatidic acid;
S1P, sphingosine-1-phosphate; PA, phosphatidic acid LPA, lysophosphatidic acid; S1P, sphingosine-1-phosphate; PA, phosphatidic acid; AGPAT, 1-acylglycerol-3-
phosphate acyltransferase; EDG, endothelial differentiation gene; LPAP, LPA phosphatase; LPP, lipid phosphate phosphatase; LYPLA, lysophospholipase; ROCK2,
Rho-associated, coiled-coil containing protein kinase 2; SGPL1, sphingosine-1-phosphate lyase 1; SGPP1, sphingosine-1-phosphatase; SPHK1, sphingosine kinase 1.
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Paired t-tests were used to compare the PCR derived expres-
sion of LPP1 during sitting with normal standing/ambulatory
activity in humans. A p < 0.05 was considered statistically
significant. All data is presented as means ± SEM.Results
Expression of hemostasis genes in skeletal muscle
Genes were identified as being involved in hemostasis by
searching PubMed and the publicly available Affymetrix
NetAffyx website for key words related to hemostasis such
as: coagulation, clotting, fibrinolysis, thrombosis, platelet
aggregation, DVT, and hemostasis. First, we began this in-
vestigation in a large number of rats and the findings justi-
fied initiating a translational study in which human biopsies
were obtained and extensively analyzed (44,792 probe sets).
Genes involved in coagulation, anti-coagulation, andfibrinolysis are listed in Tables 1 (human) and 2 (rat). The
absence and presence of expression for the set of genes
related to LPP1 signaling are listed in Table 3. For some
genes these arrays contained multiple sets of probes. Each
single probe set for the human microarray contained 11
different mRNA target sequences of 25 nucleotides, and
the results for both the better and the lower affinity probe
sets are displayed in the Tables. This expands on the few
hemostatic genes which have previously been reported to
be expressed in skeletal muscle tissue.LPP1 expression is decreased during physical inactivity
in rats
In order to identify genes potentially governing hemostasis
that are most robustly affected by physical inactivity (not
standing/ambulating) and non-exercise physical activity, we

































Figure 1 Suppression of LPP1 gene expression in rat soleus
caused by chronic physical inactivity. Rats were prevented from
standing for 10 hrs/d for 11 consecutive days. Results for two
independent sets of probes for LPP1 on the rat U34A microarray are
presented. Probe set nomenclature is from Affymetrix.com. Results are
expressed as mean ± SE. † Inactivity vs. Ambulatory Control, p < 0.05.
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ferentially expressed in the acute study (LPP1) and, simi-
larly, a gene was differentially expressed in a chronic
study (Figure 1) (also LPP1). Interestingly, even exercise on
a treadmill (30 minutes per hour) for 4 hours immediately
following inactivity was not sufficient to rapidly restore































Figure 2 Rapid suppression of LPP1 expression in rat soleus caused by
4 hours after beginning exercise. Results are expressed relative to ambulat
microarray are presented. Probe set nomenclature is from Affymetrix.com. ResLPP1 expression is decreased during physical inactivity in
humans
Similar to the findings in the rat studies, microarrays
revealed that 12 hours of physical inactivity (sitting) low-
ered LPP1 gene expression to 57 ± 9% of standing/ambu-
latory control levels (p < 0.05) (Figure 3A) in a repeated
measures design (where each subject serves as their own
control for comparison to sitting).
In accord with the microarray results, PCR results also
revealed that sitting for 12 hrs reduced LPP1 gene expres-
sion (Figure 3B). LPP1 decreased on average to 55 ± 6%
of the standing/ambulatory control values (p < 0.05).Case study
In the follow-up study to repeat these measurements over a
more extensive time course, the decrease in LPP1 expres-
sion was complete within the first day (41% of control, 3rd
bar in Figure 4) and was not decreased further after 15 days
(49% of control, 4th bar) of sitting in a wheelchair. During
the chronic inactivity, this person exercised the left leg for
one hour per day with cycle ergometry while the right leg
never exercised. This daily exercise (i.e., 1 hr of vigorous
cycling including intervals and resistance training, but no
standing/ambulating) did not attenuate the decrease in
LPP1 expression (5th bar, Figure 4). Therefore, the effect of
too much sitting overwhelmed any putative effects of exer-
cise on LPP1. Furthermore, exercise was also ineffective in
increasing LPP1 expression a month before the chronic in-
activity (2nd bar, Figure 4). We expected that LPP1 expres-











12 hours of physical inactivity is not restored by treadmill exercise
ory control rat values. Results for two sets of probes on the U34A



































































Figure 3 Suppression of LPP1 mRNA expression in human
skeletal muscle caused by 12 hours of physical inactivity.
Results are presented from (A) U133A human microarray data and
(B) reverse transcriptase PCR. GAPDH mRNA expression was not
affected by sitting. Results are expressed as mean ± SE. * vs.
Ambulatory Control, p < 0.05.
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of standing control) (6th bar, Figure 4).
Overall, these results suggest that physical inactivity (sit-
ting in humans) has a robust and rapid effect of lowering
LPP1 expression in both rats and humans. Or practically
stated, standing and ambulatory activity is sufficient to
maintain LPP1 expression at the normal level, while exer-
cise does not appear to have any effect on LPP1 expression.
Other genes related to LPP1 signaling
In addition to LPP1, there are several other lysopho-
spholipid regulating genes expressed in skeletal muscle(Table 3 and Figure 5). Another isoform of LPP1, lipid
phosphate phosphatase-3 (LPP3/PAP2B) was also signifi-
cantly expressed above background (p < 0.05), although
not significantly affected by physical inactivity. Lysopho-
sphatidic acid (LPA) is putatively one of the key lipids
involved in hemostasis, and is a substrate for LPP1. Two
enzymes involved in LPA synthesis, lysophospholipase I
(LYPLA1) and lysophospholipase II (LYPLA2), were sig-
nificantly expressed in tandem with other genes in this
pathway (p < 0.05). Three enzymes responsible for the
transformation of LPA to phosphatidic acid (an initial
step in triglyceride synthesis), lysophosphatidic acid
acyltransferase-alpha (AGPAT1), lysophosphatidic acid
acyltransferase-beta (AGPAT2), and lysophosphatidic
acid acyltransferase-delta (AGPAT3) were significantly
expressed. Of the LPA receptors (EDG2, EDG3, EDG4,
EDG7) and the S-1-P receptor (EDG8), only EDG2 ([19]
LPA1 receptor) was moderately expressed in human
skeletal muscle. The current understanding of the rela-
tionship between these genes is schematically repre-
sented in Figure 5.
Discussion
This is the first study to comprehensively identify
hemostasis related genes in both rodent and human
skeletal muscle with microarray technology. We confirm
the presence of a couple of previously reported genes
(tPA and tetranectin) and extend this list to at least an-
other 15 transcripts significantly expressed above back-
ground in skeletal muscle that have known roles in
coagulation and fibrinolysis. Furthermore, we identified
a potentially novel candidate gene, LPP1, that was sensi-
tive to physical inactivity in both rat and human skeletal
muscle, explaining why physical inactivity (too much
prolonged sitting) may increase the risk for thrombosis.
Because physical inactivity (e.g., sitting) is associated
with DVT [4-6,11] and changes in the contractile state
of muscle, we first raised the hypothesis in 2007 [3] that
a change in the expression of a key gene(s) in deep skel-
etal muscle tissue would be evident and it could be a
distinct response to the physiology of inactivity (sitting
too much) apart from recommended exercise. LPP1,
with a proposed antagonistic role in platelet aggregation
[20] and inflammation [21], was significantly decreased
in both the human and rat studies of muscular inactivity.
LPP1 was decreased with both acute and chronic reduc-
tions in normal daily contractile activity but was not
impacted by exercise.
We used Affymetrix microarrays with probes for over
44,000 human transcripts. From this search we identified
23 transcripts from genes with functions related to
hemostasis that were at least moderately expressed
according to Affymetrix standards in human muscle








































Figure 4 Case study on the effect of several levels of physical activity on LPP1 expression in deep human skeletal muscle. A healthy
male subject (25 yrs.) was the tissue donor for all of the repeated measures treatments. The standing/ambulatory control day was normal to low-
intensity puttering for 12 hours before the muscle biopsy. During the exercise day, the subject performed aerobic exercise (cycle ergometry and
treadmill walking) in addition to normal spontaneous standing/ambulatory activity. For chronic inactivity, the subject sat in a wheelchair for
15 days and exercised one leg daily (but without adding back the natural standing and other low-intensity physical activity), while the other leg
never received exercise. After 16 days of sitting, the subject returned to daily standing/ambulatory activity for 12 hours immediately preceding a
final biopsy. Diet was controlled the day of and the day before all muscle biopsies which were all taken at the same time of day. Error bars are
shown to indicate the variability (SD) between repeated biopsies on the same day.
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[12,13]. Importantly, the more definitive detection of
tPA (and tetranectin) at the mRNA level in human
muscle [13] is consistent with our findings that one of
the sources for these and other hemostatic factors could
be within the muscle tissue itself, rather than indirect ac-
cumulation of the protein from the blood. We have here
confirmed and extended these observations to other













Figure 5 Interaction of genes involved in lysophospholipid metabolis
regulating these pathways. The enzymes are in boxes and each is known t
skeletal muscle tissue expresses a key LPA receptor (EDG2), and expresses a
platelet aggregation, ROCK2 has been associated with inflammation. The re
pathways would lead to an attenuation of LPA effects. Of these genes, onl
lysophosphatidylcholine; LPA, lysophosphatidic acid; AGPAT, 1-acylglycerol-
LPP, lipid phosphate phosphatase; LYPLA, lysophospholipase; ROCK2, Rho-aannexin A2), and also to genes involved in blood coagu-
lation (i.e., Factors VII and VIII, thrombin receptor, and
vWF). Furthermore, the mRNA for two enzymes,
gamma-glutamyl carboxylase and vitamin K epoxide re-
ductase, necessary for the synthesis of coagulation fac-
tors, were expressed in skeletal muscle. Despite some
differences in muscle fiber type between species, all of
the genes with anti-coagulant and fibrinolytic functions












m. The novel finding is that skeletal muscle tissue expresses the genes
o catalyze the reaction in the figure. The new data demonstrates that
Rho kinase (ROCK2) well-known to be activated by LPA. In addition to
d pathway indicates a pathway to inflammation and the blue
y LPP1 is affected by physical inactivity. Abbreviations: LPC,
3-phosphate acyltransferase; EDG2, endothelial differentiation gene 2;
ssociated, coiled-coil containing protein kinase 2.
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phate diphosphohydrolase 1, protein S (alpha), thrombo-
modulin, tPA, annexin A2, uPA). This agrees with a
general tenet in muscle physiology that skeletal muscle
is relatively conserved between species compared to
other tissues. This observation of similar anti-coagulant
and fibronolytic genes being expressed in the skeletal
muscle of both rats and humans would support the use
of rodent models in translational studies of muscle and
hemostasis.
The new knowledge that LPP1 is expressed in leg
tissue differentially by physical activity patterns is sig-
nificant because it provides the first study we are
aware of on the physiological regulation of this gene.
LPP1 mRNA encodes a 32 kDa transmembrane ecto-
enzyme responsible for the degradation of the extra-
cellular bioactive phospholipids by dephosphorylation.
Lysophosphatidic acid (LPA), sphingosine-1-phosphate,
ceramide-1-phosphate, and phosphatidic acid are all
substrates for LPP1. LPA is arguably the most important
of these lipids because it has the highest affinity for
LPP1, and even more importantly, because LPA has re-
cently emerged as a potent stimulator of platelet aggre-
gation [20,22-25], platelet monocyte aggregation [20],
tissue factor expression [26], fibronectin matrix [27],
and inflammation [21,28,29]. Similarly, sphingosine-1-
phosphate has been shown to stimulate platelets to
bind and assemble fibronectin [27], stimulate tissue fac-
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Figure 6 Relationship between hemostatic gene function, physical in
muscle expresses distinct groups of genes involved in hemostasis (fibrinoly
the synthesis of these factors). Of all these genes expressed in skeletal mus
in humans). Sitting in humans and the removal of standing in rats suppres
indicated that DVT is a complex disorder and caused by many interacting
expression deep in skeletal muscle could be a contributing factor. Many ca
deposition are presently reported to be expressed in muscle tissues (Tables
of those could be regulated post-transcriptionally, LPP1 mRNA was signific
that LPP1 attenuates platelet aggregation, fibrin deposition, and inflammat
frequent and higher intensity type of exercise more commonly associated
decrease in LPP1 expression. Items in red would favor a prothrombotic staand sphingosine-1-phosphate are released from acti-
vated platelets and are thought to promote a positive
feedback on platelet aggregation. Haseruck et al. [20]
argued that the expression of LPP1 on the endothelium
of tissues (such as the endothelium in muscle tissue)
would attenuate local accumulation of LPA and thus
limit platelet activation [20]. In cell culture experiments
where LPP1 expression has been manipulated, LPP1
has been shown to be important for the attenuation of
several atherothrombogenic and malignant processes
induced by LPA, including platelet aggregation [25], the
release of the proinflammatory cytokine IL-8 [22], and
ovarian cancer cell proliferation [32]. There are several
lines of evidence that LPP1 can also attenuate the sig-
naling of other factors including the prothrombotic and
proinflammatory cytokine TNFα [21] and thrombin
[19]. Therefore, if the protein is regulated by its gene
expression, LPP1 would be a novel candidate for why
physical inactivity is a risk factor for DVT or other
types of thrombosis (Figure 6).
Other genes involved in LPA metabolism were
detected in skeletal muscle (Table 3 and Figure 5). An
isoform of LPP1, LPP3, is significantly expressed in
human skeletal muscle and is similar to LPP1 in that it
degrades extracellular LPA and has been shown to at-
tenuate LPA induced signaling in ovarian malignant epi-
thelial cell cultures [33]. In contrast to LPP1’s location
on the apical side of endothelial cells, LPP3 is thought to
be located on the basolateral membrane of endothelialtic Factors
 Thrombin
Coag. Factor Synthesis in Muscle











activity, LPP1 and risk of deep venous thrombosis. Human skeletal
sis, anti-coagulation, and coagulation factors, and enzymes involved in
cle, only LPP1 expression was affected by physical inactivity (i.e., sitting
sed LPP1 expression in skeletal muscle tissue. Prior studies have
factors. We propose the novel hypothesis that the local gene
ndidate genes known to regulate platelet aggregation and fibrin
1 and 2) and are presented here as four distinct groups. While some
antly decreased by physical inactivity. Prior published work indicates
ion. Ordinary non-exercise movements and standing, unlike the less
with a boost in muscular strength or cardiovascular fitness, prevent the
te while those in blue would be anti-thrombotic.
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lysophosphatidylcholine to LPA, lysophospholipase I,
was strongly detected in both human and rat skeletal
muscle and, therefore, may play a local role in LPA
production.
Limitations
Although we present robust data showing that physical
inactivity can reduce LPP1 transcript level, we did not
determine if this was due to a reduction in transcription
(possibly secondary to epigenetic changes to chromatin
or DNA) or a reduction in mRNA stability or both. In
addition, we report only on the mRNA level of this gene
and not on the protein as there are not good antibodies
yet available for this transmembrane protein. As we tested
only lean and apparently healthy rats and humans we can-
not determine that LPP1 expression would be responsive
to physical inactivity in a more diseased population.
Conclusions
This study raises the novel hypothesis that muscle disuse
may contribute to hemostatic disorders not simply because
of factors related to reduced blood flow, but also poten-
tially because of the diverse repertoire of hemostatic genes
expressed locally in muscles, such as LPP1. These findings
highlight the importance of the concept of inactivity physi-
ology where processes engaged by physical inactivity (not
standing or ambulating) are not necessarily the opposite of
exercise [3]. This might explain why exercise in the
present study was ineffective at counteracting the effects
of physical inactivity (Figures 2 and 4). There is little doubt
that DVT is not caused by a lack of participation in exer-
cise training programs, but it appears that DVT is caused
in part by the absence of the frequent contractions nor-
mally associated with low-intensity movements through-
out the day. The preliminary findings of this study need
to be investigated at multiple scientific levels to under-
stand the putative role of LPP1 and lysophospholipid
metabolism in risk for thrombosis associated with a lack
of skeletal muscle contractile activity. Finally, these find-
ings of a number of hemostatic genes expressed in ske-
letal muscle may emphasize the potential role of skeletal
muscle in health and disease as more than simply con-
tractile machinery.
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